Fractures of the Proximal Tibia Associated with Longterm Use of Methotrexate: 3 Case Reports and a Review of Literature

To the Editor:

There are several therapeutic options for which methotrexate (MTX) represents an excellent choice as systemic therapy for mild to severe psoriasis, psoriatic arthritis, and rheumatoid arthritis (RA). MTX is a folic acid antagonist, inhibiting dihydrofolate reductase, an enzyme that converts dihydrofolate to tetrahydrofolate. Impedance of this reaction interferes with purine synthesis and DNA biosynthesis, resulting in dysfunction of DNA replication, followed by cell death. MTX is commonly used in high doses for the treatment of malignancies, and in lower doses (up to 30 mg once weekly) for autoimmune diseases such as RA and psoriasis.

MTX osteopathy was first described in children with leukemia who were treated with high doses of MTX and was characterized by bone pain, localized osteopenia, and sometimes even microfractures. Some studies suggest also that longterm use of low-dose MTX can aggravate the development of osteopenia and stress fractures.

Here we describe 3 patients with proximal tibia fractures treated with a low to intermediate dose of MTX.

Case 1. A 51-year-old white woman presented with increasing pain in both knees. Her medical history included a left ankle fracture, a right meniscectomy, and enthesopathy based on psoriasis. Her body weight was 80 kg with a height of 165 cm. She denied any severe trauma preceding her complaints. Her family history was negative for rheumatism and associated symptoms and she has been treated for psoriasis with MTX (maximum dosage 15 mg once weekly) for 12 years. Further medication included pantoprazole (20 mg once daily) and mianserin (30 mg once daily). Folic acid was not prescribed, nor was preventive medication for osteoporosis such as calcium or bisphosphonates.

On physical examination there were no signs of arthritis. Both knees had crepitus with flexion and extension. The left knee especially was very painful on examination. Radiographs of both knees showed a transverse mainly consolidated medial tibia fracture with periostal callus formation that was more distinct on the left side than on the right (Figure 1). Magnetic resonance imaging (MRI) with gadolinium showed a fracture of the left proximal tibia plateau (coronal T1-weighted sequence; Figure 2).

Figure 1. Anteroposterior radiograph of the left knee shows a transverse fracture of the proximal tibial metaphysis with fracture margin sclerosis (arrow).
Laboratory tests showed an increased alkaline phosphatase of 190 U/l corresponding with increased bone turnover often seen in a fracture. Other laboratory tests were normal. Dual energy x-ray absorptiometry (DEXA) showed osteopenia. The results of the bone mineral density (BMD) of the lumbar were a T score of –1.1 and –0.8 of the total hip. A bone biopsy of the left tibia plateau was taken. The histological findings showed signs of increased bone turnover and fibrosis of the bone marrow without signs of osteoporosis or osteonecrosis. There were no signs of a malignancy. Treatment with MTX was discontinued and the patient was treated with etoricoxib (90 mg once daily) and etanercept. A splint was applied as conservative therapy. Symptoms stopped after a few weeks.

Case 2. A 77-year-old white woman with a progressive, erosive, rheumatoid factor–positive RA and a mild psoriasis was treated with different doses of MTX for 11 years. Her current medication included pantoprazole (20 mg once daily), naproxen (500 mg twice daily), folic acid (5 mg once weekly), etanercept (50 mg subcutaneously once weekly), leflunomide (10 mg once daily), and MTX (25 mg subcutaneously once weekly). She did not use preventive medication for osteoporosis. In the past she had been treated with low doses of prednisolone for a short duration. Her other medical history included a total hip procedure on both right sides, a femur fracture, and a mild psoriasis. Her body weight was 62 kg with a height of 155 cm.

Eight years after diagnosis of RA, she presented herself with severe pain in her proximal left tibia that prevented her from walking and was relieved by rest. Physical examination disclosed severe tenderness on the tibia with a mild edema. Radiographs of the knees showed signs of osteoarthritis on both sides without any other pathology. Because of ongoing pain in the left knee, an additional MRI was done. The MRI showed signs of a fracture in the medial side of the proximal tibia with local bone marrow edema (Figure 3). Laboratory tests showed an elevated erythrocyte sedimentation rate (ESR) of 71 mm/h and an increased alkaline phosphatase of 133 U/l. DEXA showed osteopenia of the lumbar spine (BMD T score –1.3). A bone biopsy was not taken. MTX therapy was stopped and other medication was continued. A splint was applied as conservative therapy. MTX was restarted after a few weeks because of RA activity. A few months later she died of a nonrelated disease in the intensive care unit.

Case 3. A 68-year-old white man with RA for almost 35 years was treated with different doses of MTX for 9 years. His current medication included MTX (25 mg subcutaneously, once weekly), folic acid (5 mg once weekly), hydroxychloroquine (200 mg once daily), and omeprazole (20 mg once daily). He did not use preventive medication for osteoporosis. His body weight was 86 kg with a height of 174 cm. His other medical history included a fracture of his right elbow.

After 25 years with RA, radiographs of his hands, feet, shoulders, and knees did not show any abnormalities. Initially, radiographs of the knees 2 months before fracture showed osteoarthritis but a normal calcareous skeleton. At the time of the fracture an MRI was done because of knee pain unrelated to RA. The MRI showed a fracture in the medial side of the proximal tibia (Figure 4). Laboratory tests showed an ESR of 31 mm/h and an
Figure 3. Coronal fat-suppressed T2-weighted magnetic resonance image shows a hypointense transverse fracture of cancellous and cortical bone of the proximal tibial metaphysis. There is associated bone marrow and periosteal edema.

Figure 4. Coronal T1-weighted magnetic resonance image shows a fracture of the medial tibia plateau, not an intraarticular fracture. It is a hypointense transverse fracture of cancellous and cortical bone of the proximal tibial metaphysis. There is associated bone marrow and periosteal edema.
alkaline phosphatase level of 104 U/l. DEXA of the lumbar spine showed a normal T score (BMD T score +0.3). DEXA of total hip showed osteopenia with a T score of –2.4. MTX therapy was stopped, but continued after 3 months because of RA activity. The fracture has healed without residual damage. The patient’s pain subsided quickly.

MTX, an antimetabolite, is a folic acid antagonist and in oncology it is usually given orally but also can be given intramuscularly, intravenously, or intrathecally, depending on the type of cancer6. MTX competitively inhibits the reduction of tetrahydrofolate by dihydrofolate reductase, thus inhibiting the synthesis of DNA and RNA1. The drug is commonly used at high doses (100-1000 mg/m²) in the treatment of lymphoma, lymphoblastic leukemia, and osteosarcoma. In autoimmune diseases, MTX is used at low doses (up to 30 mg once weekly) given orally or by intramuscular or subcutaneous injections1. It has antiinflammatory and cytokine-modulating properties that are thought to contribute to the beneficial effect of MTX in the treatment of RA and other chronic inflammatory conditions such as psoriasis and psoriatic arthritis8. Complications of MTX, which include hematological and hepatic adverse events and less frequently lung or bone marrow toxicities, are well known and may easily be detected by careful monitoring of hematological measurements and renal and hepatic functions3.

The use of high-dose MTX has been associated with osteopathy, characterized by severe bone pain, localized osteoporosis, and even spontaneous insufficient fractures of the lower extremities3. But there also have been reports of fragility fractures (e.g., fractures that result from mechanical forces that would ordinarily not cause fractures and that reflect poor bone quality) occurring in adult patients taking longterm, low to intermediate doses of MTX for RA, psoriasis, and/or psoriatic arthritis9,10,11,12,13,14. MTX can damage bone in 2 ways, possibly leading to osteopathy. Previous studies showed increased urinary and fecal excretion of calcium in MTX use, indicating enhanced osteoclastic bone resorption10,15. Other investigations showed that short-term administration of MTX in rats produced toxic effects on osteoblasts, with a 60% reduction in the rate of bone formation, resulting in decreased osteoid volume and thickness16. Reduced bone turnover by these 2 mechanisms could predispose patients to delayed microfracture repair, with osteopathy as a result9. Van Leeuwen et al said that clinical studies with multiagent chemotherapy have demonstrated that antimetabolites decrease bone growth and final height17. He also described the effect of MTX on the growth of male Wistar rats. Treatment with MTX reduces the proximal tibial growth plate shear strength because of a decreased surface area and maximum shear stress18.

Although the presence of osteopathy in patients with inflammatory conditions treated with longterm and short-term low-dose MTX has been reported, with resolution of the symptoms on withdrawal of MTX, it is still debated19,20. Minaur et al reported results in a prospective nonrandomized trial with 116 non–steroid-treated RA subjects that suggest that MTX is safe for bone health at a low dose (10-15 mg once weekly)21. A critical review of published reports suggests that most patients treated with low-dose MTX do not have an increased risk of MTX osteopathy22. Buckley et al showed that longterm low-dose administration of MTX does lead to reduced bone density in patients treated with the combination MTX plus prednisolone more than in patients treated with prednisolone alone23. Preston et al reported cases of osteopathy in postmenopausal women taking low-dose MTX, indicating this hormonal status to be of attributional importance9.

Fragility fractures have been reported mainly at the distal tibia site in subjects taking low doses of MTX9,10,11. Here we present 3 patients who developed fragility fractures at the proximal tibia site during longterm low-dose to intermediate-dose MTX treatment. To our knowledge this has not been described before. Two patients had been treated with oral glucocorticoids in the past for a maximum of 2 years. The dosage was 5 or 10 mg once daily. Glucocorticoids are known for damaging bone metabolism. In our patients, glucocorticoid treatment can be ruled out as a possible cause of the fractures. In none of the patients were there signs of osteoporosis. DEXA showed osteopenia in all 3 patients. Osteopathy is a rare and relatively unknown complication during MTX treatment; precise incidence numbers are lacking. Mainly the distal tibia is at risk for fragility fractures during MTX treatment.

BMD measurement showed only osteopenia but bone strength is determined by bone mass, geometry, and quality. The latter includes several aspects of bone structure and composition, including bone turnover, microarchitecture, the degree and distribution of mineralization, the extent of microdamage and its repair, and finally, the composition of bone matrix and mineral22. BMD measurement does not show all these components.

We described 3 patients taking longterm low-dose to intermediate-dose MTX therapy with a fracture of the proximal tibia, presumably caused by MTX treatment. It is important to become aware of this side effect in distal as well as proximal tibia as the only therapy is withdrawal of MTX. Therefore we would like to emphasize the importance of keeping osteopathy in mind when patients being treated with longterm low to intermediate MTX complain of knee pain. Further, negative results in knee radiographs do not exclude pathology, and for patients with persistent complaints an MRI should be performed.

LOUISE MEIER, ms., Department of Rheumatology, Máxima Medical Center Eindhoven; ANNE-MOON van TUYLL van SERSOOSKERKEN, md, Department of Dermatology, University Hospital Maastricht; ELLEN LIBERTON, md, Department of Dermatology; LUCAS KLEIJN, MD, Department of Orthopedic Surgery, Elzerick Hospital Helmond; TOON WESTGEEST, MD, Department of Rheumatology; MARTIN POLAK, MD, Department of Radiology; RON de NIJS, PhD, Department of Rheumatology, Máxima Medical Center Eindhoven, The Netherlands. Address correspondence to L. Meier, Department of Rheumatology, Máxima Medical Center Eindhoven, Postbox 90052, 5600PD Eindhoven, The Netherlands. E-mail: L.Meier@mmc.nl

REFERENCES


J Rheumatol 2010;37:11; doi:10.3899/jrheum.100385